| 1 |
| Authors | R.F. Baggaley, J.T. Griffin, R. Chapman, T.D. Hollingsworth, N. Nagot, S. Delany, P. Mayaud, F. de Wolf, C. Fraser, A.C. Ghani, H.A. Weiss | | Title | Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load |
| Journal | AIDS |
| Volume | 23 |
| Year | 2009 |
| Issue | 8 |
| Pages | 1005-1013 |
| ISSN | 02699370 |
| Faculty | AMC-UvA |
| Abstract | Objective: Trials of herpes simplex virus (HSV) suppressive therapy among HSV-2/HIV-1-infected individuals have reported an impacton plasma HIV-1 viral loads(PVLs). Our aim was to estimate the population-level impact of suppressive therapy on female-to-male HIV-1 sexual transmission. Design and methods: By comparing prerandomization and postrandomization individual-level PVL data from the first two HSV suppressive therapy randomized controlled trials in sub-Saharan Africa, we estimated the effect of treatment on duration of asymptomatic infection and number of HIV-1 transmission events for each trial. Results: Assuming that a reduction in PVL is accompanied by an increased duration of HIV-1 asymptomatic infection, 4-6 years of HSV suppressive therapy produce a 1-year increase in the duration of this stage. To avert one HIV-1 transmission requires 8.8 [95% confidence interval (CI), 5.9-14.9] and 11.4 (95% Cl, 7.8-27.5) women to be treated from halfway through their HIV-1 asymptomatic period, using results from Burkina Faso and South African trials, respectively. Regardless of the timing of treatment initiation, 51.6 (95% Cl, 30.4-137.0) and 66.5 (95% Cl, 36.7-222.6) treatment-years are required to avert one HIV-1 infection. Distributions of set-point PVL values from sub-Saharan African populations suggest that unintended adverse consequences of therapy at the population level (i.e. increased HIV-1 transmission due to increased duration of infection) are unlikely to occur in these settings. Conclusion: HSV suppressive therapy may avert relatively few HIV-1 transmission events per person-year of treatment. Its use as a prevention intervention may be limited; however, further research into its effect on rate of CD4 cell count decline and the impact of higher dosing schedules is warranted. (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins |
| Document type | Article |
| Document finder | 
|
Use this url to link to this page: http://dare.uva.nl/en/record/355230
Contact us about this recordNotify a colleague
Add to bookbag
|
